OTC Products is Instructional Biology's line of non-prescription, over-the-counter products: dietary supplements, and transmucosal products, which are absorbed through a mucous membrane such as the lining of the mouth.

OTC Products, revenue stream 05 of 10: on the seven-stage pipeline (Discovery, Development, Testing, Prototype, Ready for Demo, IND if required, Sales) it is at Sales. Protected by: OTC Products, Composition of Matter, Provenance and Release. What it is: Sold without a prescription: dietary-supplement and transmucosal products. Markets its segments address: Dietary supplements, USD 209.5 bn (2025), 8.9% CAGR; Cosmeceuticals, USD 71.23 bn (2025), 8.83% CAGR; Peptide therapeutics, USD 52.59 bn (2025), 5.19% CAGR; Anti-counterfeit pharmaceutical and cosmetics packaging, USD 108.9 bn (2024), 8.6% CAGR.
OTC Products at a glance: its stage, the segments that protect it and the markets they address, as of October 29, 2026.

Where It Stands

OTC Products is at Sales, the last of the seven stages on Our Pipeline: Discovery, Development, Testing, Prototype, Ready for Demo, IND (if required) and Sales. It is the first of our ten revenue streams to reach Sales.

The Segments That Protect It

Three segments of our IP portfolio protect this stream. OTC Products covers the products themselves. Composition of Matter covers what they are made of. Provenance and Release covers where each lot's material comes from and how each lot is certified before it is released. The same three segments protect our Cosmeceuticals, and Composition of Matter and Provenance and Release also protect our Therapeutics & Vanguard Assets.

The Markets Behind Its Segments

Each segment of our IP portfolio addresses a market that independent research firms already measure. The table gives each market's latest published size, its forecast and its compound annual growth rate (CAGR), from the same sources as Ten Revenue Streams.

Market and segmentSizeForecastCAGR
Dietary supplements [1]
OTC Products
USD 209.5 bn (2025)USD 414.52 bn by 20338.9%
Cosmeceuticals [2]
OTC Products
USD 71.23 bn (2025)USD 152.58 bn by 20348.83%
Peptide therapeutics [3]
Composition of Matter
USD 52.59 bn (2025)USD 87.21 bn by 20355.19%
Anti-counterfeit pharmaceutical and cosmetics packaging [4]
Provenance and Release
USD 108.9 bn (2024)USD 248.9 bn by 20348.6%

These are estimates of whole markets, not Instructional Biology revenue or forecasts.

For partnership or licensing conversations about OTC Products, see Partnerships and Licensing.

Sources

  1. Grand View Research, dietary supplements market. nutraceuticalbusinessreview.com · bolsamania.com
  2. Precedence Research, cosmeceuticals market. precedenceresearch.com
  3. Precedence Research, peptide therapeutics market. precedenceresearch.com
  4. Global Insight Services, anti-counterfeit pharmaceutical and cosmetics packaging market. giiresearch.com
Our over-the-counter products are not intended to diagnose, treat, cure or prevent any disease. Market figures are third-party estimates of whole markets, not Instructional Biology revenue or forecasts. Nothing on this page is medical advice.
← Back to Ten Revenue Streams